Home > Clinical Trials
Check All Search

Saved trials

COMPLETED
NCT04687761
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
113 Enrollment(s)
15 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Leukemia, Myeloid, Acute


De Novo


Age More 60yr
RECRUITING
NCT06821191
Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study
78 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Coronary Artery Disease
RECRUITING
NCT07497386
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
150 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Unresectable Locally Recurrent Breast Cancer


Unresectable Locally Metastatic Breast Cancer
NOT_YET_RECRUITING
NCT07547878
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
64 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Chronic Kidney Disease


Type 2 Diabetes
ACTIVE_NOT_RECRUITING
NCT06048718
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases
28 Enrollment(s)
13 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer


Metastatic Breast Cancer
NOT_YET_RECRUITING
NCT07574320
Effect of Ramosetron in Patients With Diarrhea Predominant Irritable Bowel Syndrome
76 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
IBS-D (Diarrhea-predominant)
ACTIVE_NOT_RECRUITING
NCT04493138
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
30 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Chronic Myelomonocytic Leukemia


Myelodysplastic Syndrome


Myeloproliferative Neoplasm


Recurrent Chronic Myelomonocytic Leukemia


Recurrent Myelodysplastic Syndrome


Recurrent Myeloproliferative Neoplasm
ACTIVE_NOT_RECRUITING
NCT06172127
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
165 Enrollment(s)
36 Study location(s)
INTERVENTIONAL (PHASE2)
HER2-positive Breast Cancer